Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38


Boosting Interleukin-12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR-Tagged Nanogold.

Gasparri AM, Sacchi A, Basso V, Cortesi F, Freschi M, Rrapaj E, Bellone M, Casorati G, Dellabona P, Mondino A, Corti A, Curnis F.

Small. 2019 Sep 16:e1903462. doi: 10.1002/smll.201903462. [Epub ahead of print]


Physiological levels of chromogranin A prevent doxorubicin-induced cardiotoxicity without impairing its anticancer activity.

Rocca C, Scavello F, Colombo B, Gasparri AM, Dallatomasina A, Granieri MC, Amelio D, Pasqua T, Cerra MC, Tota B, Corti A, Angelone T.

FASEB J. 2019 Jun;33(6):7734-7747. doi: 10.1096/fj.201802707R. Epub 2019 Apr 11.


Spatiotemporal Regulation of Tumor Angiogenesis by Circulating Chromogranin A Cleavage and Neuropilin-1 Engagement.

Dallatomasina A, Gasparri AM, Colombo B, Sacchi A, Bianco M, Daniele T, Esposito A, Pastorino F, Ponzoni M, Marcucci F, Curnis F, Corti A.

Cancer Res. 2019 Apr 15;79(8):1925-1937. doi: 10.1158/0008-5472.CAN-18-0289. Epub 2019 Feb 22.


Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis.

Maugeri N, Capobianco A, Rovere-Querini P, Ramirez GA, Tombetti E, Valle PD, Monno A, D'Alberti V, Gasparri AM, Franchini S, D'Angelo A, Bianchi ME, Manfredi AA.

Sci Transl Med. 2018 Jul 25;10(451). pii: eaao3089. doi: 10.1126/scitranslmed.aao3089.


Glycine N-methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing.

Corti A, Gasparri AM, Ghitti M, Sacchi A, Sudati F, Fiocchi M, Buttiglione V, Perani L, Gori A, Valtorta S, Moresco RM, Pastorino F, Ponzoni M, Musco G, Curnis F.

Adv Funct Mater. 2017 Sep 26;27(36). pii: 1701245. doi: 10.1002/adfm.201701245.


Regulation of tumor growth by circulating full-length chromogranin A.

Curnis F, Dallatomasina A, Bianco M, Gasparri A, Sacchi A, Colombo B, Fiocchi M, Perani L, Venturini M, Tacchetti C, Sen S, Borges R, Dondossola E, Esposito A, Mahata SK, Corti A.

Oncotarget. 2016 Nov 8;7(45):72716-72732. doi: 10.18632/oncotarget.12237.


NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors.

Curnis F, Fiocchi M, Sacchi A, Gori A, Gasparri A, Corti A.

Nano Res. 2016 May;9(5):1393-1408. Epub 2016 Mar 4.


Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models.

Bianco M, Gasparri A, Generoso L, Assi E, Colombo B, Scarfò L, Bertilaccio MT, Scielzo C, Ranghetti P, Dondossola E, Ponzoni M, Caligaris-Cappio F, Ghia P, Corti A.

Oncotarget. 2016 Jul 5;7(27):41725-41736. doi: 10.18632/oncotarget.9407.


Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients.

Bianco M, Gasparri AM, Colombo B, Curnis F, Girlanda S, Ponzoni M, Bertilaccio MT, Calcinotto A, Sacchi A, Ferrero E, Ferrarini M, Chesi M, Bergsagel PL, Bellone M, Tonon G, Ciceri F, Marcatti M, Caligaris-Cappio F, Corti A.

Cancer Res. 2016 Apr 1;76(7):1781-91. doi: 10.1158/0008-5472.CAN-15-1637. Epub 2016 Feb 11.


Rigidity-Preserving Team Partitions in Multiagent Networks.

Carboni D, Williams RK, Gasparri A, Ulivi G, Sukhatme GS.

IEEE Trans Cybern. 2015 Dec;45(12):2640-53. doi: 10.1109/TCYB.2014.2378552. Epub 2014 Dec 30.


A new chromogranin A-dependent angiogenic switch activated by thrombin.

Crippa L, Bianco M, Colombo B, Gasparri AM, Ferrero E, Loh YP, Curnis F, Corti A.

Blood. 2013 Jan 10;121(2):392-402. doi: 10.1182/blood-2012-05-430314. Epub 2012 Nov 27.


IsoDGR-tagged albumin: a new αvβ3 selective carrier for nanodrug delivery to tumors.

Curnis F, Sacchi A, Longhi R, Colombo B, Gasparri A, Corti A.

Small. 2013 Mar 11;9(5):673-8. doi: 10.1002/smll.201202310. Epub 2012 Nov 12.


Chromogranin A binds to αvβ6-integrin and promotes wound healing in mice.

Curnis F, Gasparri AM, Longhi R, Colombo B, D'Alessio S, Pastorino F, Ponzoni M, Corti A.

Cell Mol Life Sci. 2012 Aug;69(16):2791-803. doi: 10.1007/s00018-012-0955-z. Epub 2012 Mar 14.


The N-terminal fragment of chromogranin A, vasostatin-1 protects mice from acute or chronic colitis upon oral administration.

Rumio C, Dusio GF, Colombo B, Gasparri A, Cardani D, Marcucci F, Corti A.

Dig Dis Sci. 2012 May;57(5):1227-37. doi: 10.1007/s10620-012-2031-9. Epub 2012 Jan 26.


A networked transferable belief model approach for distributed data aggregation.

Gasparri A, Fiorini F, Di Rocco M, Panzieri S.

IEEE Trans Syst Man Cybern B Cybern. 2012 Apr;42(2):391-405. doi: 10.1109/TSMCB.2011.2166955. Epub 2011 Oct 20.


Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy.

Dondossola E, Gasparri AM, Colombo B, Sacchi A, Curnis F, Corti A.

Cancer Res. 2011 Sep 1;71(17):5881-90. doi: 10.1158/0008-5472.CAN-11-1273. Epub 2011 Jul 28.


Role of vasostatin-1 C-terminal region in fibroblast cell adhesion.

Dondossola E, Gasparri A, Bachi A, Longhi R, Metz-Boutigue MH, Tota B, Helle KB, Curnis F, Corti A.

Cell Mol Life Sci. 2010 Jun;67(12):2107-18. doi: 10.1007/s00018-010-0319-5. Epub 2010 Mar 9.


Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching.

Curnis F, Cattaneo A, Longhi R, Sacchi A, Gasparri AM, Pastorino F, Di Matteo P, Traversari C, Bachi A, Ponzoni M, Rizzardi GP, Corti A.

J Biol Chem. 2010 Mar 19;285(12):9114-23. doi: 10.1074/jbc.M109.044297. Epub 2010 Jan 11.


Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma.

Gasparri AM, Jachetti E, Colombo B, Sacchi A, Curnis F, Rizzardi GP, Traversari C, Bellone M, Corti A.

Mol Cancer Ther. 2008 Dec;7(12):3859-66. doi: 10.1158/1535-7163.MCT-08-0538.


Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif.

Curnis F, Sacchi A, Gasparri A, Longhi R, Bachi A, Doglioni C, Bordignon C, Traversari C, Rizzardi GP, Corti A.

Cancer Res. 2008 Sep 1;68(17):7073-82. doi: 10.1158/0008-5472.CAN-08-1272.


Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.

Crippa L, Gasparri A, Sacchi A, Ferrero E, Curnis F, Corti A.

Cancer Res. 2008 Feb 15;68(4):1154-61. doi: 10.1158/0008-5472.CAN-07-2085.


Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha.

Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A.

Clin Cancer Res. 2006 Jan 1;12(1):175-82.


Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms.

Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A.

Cancer Res. 2005 Apr 1;65(7):2906-13.


Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity.

Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A.

Cancer Res. 2004 Jan 15;64(2):565-71.


Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif.

Colombo G, Curnis F, De Mori GM, Gasparri A, Longoni C, Sacchi A, Longhi R, Corti A.

J Biol Chem. 2002 Dec 6;277(49):47891-7. Epub 2002 Oct 7.


Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A.

Nat Biotechnol. 2000 Nov;18(11):1185-90.


Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells.

Ratti S, Curnis F, Longhi R, Colombo B, Gasparri A, Magni F, Manera E, Metz-Boutigue MH, Corti A.

J Biol Chem. 2000 Sep 22;275(38):29257-63.


Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models.

Gasparri A, Moro M, Curnis F, Sacchi A, Pagano S, Veglia F, Casorati G, Siccardi AG, Dellabona P, Corti A.

Cancer Res. 1999 Jun 15;59(12):2917-23.


Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.

Moro M, Gasparri AM, Pagano S, Bellone M, Tornaghi P, Veglia F, Corti A, Casorati G, Dellabona P.

Cancer Res. 1999 Jun 1;59(11):2650-6.


Tumor targeting with biotinylated tumor necrosis factor alpha: structure-activity relationships and mechanism of action on avidin pretargeted tumor cells.

Corti A, Gasparri A, Sacchi A, Curnis F, Sangregorio R, Colombo B, Siccardi AG, Magni F.

Cancer Res. 1998 Sep 1;58(17):3866-72.


Production and structure characterisation of recombinant chromogranin A N-terminal fragments (vasostatins) -- evidence of dimer-monomer equilibria.

Corti A, Sanchez LP, Gasparri A, Curnis F, Longhi R, Brandazza A, Siccardi AG, Sidoli A.

Eur J Biochem. 1997 Sep 15;248(3):692-9.


Chromogranin A fragments modulate cell adhesion. Identification and characterization of a pro-adhesive domain.

Gasparri A, Sidoli A, Sanchez LP, Longhi R, Siccardi AG, Marchisio PC, Corti A.

J Biol Chem. 1997 Aug 15;272(33):20835-43.


Characterisation of circulating chromogranin A in human cancer patients.

Corti A, Gasparri A, Chen FX, Pelagi M, Brandazza A, Sidoli A, Siccardi AG.

Br J Cancer. 1996 Apr;73(8):924-32.


Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals.

Burastero SE, Gaffi D, Lopalco L, Tambussi G, Borgonovo B, De Santis C, Abecasis C, Robbioni P, Gasparri A, Lazzarin A, Celada F, Siccardi AG, Beretta A.

AIDS Res Hum Retroviruses. 1996 Mar 1;12(4):273-80.


Antigenic regions of human chromogranin A and their topographic relationships with structural/functional domains.

Corti A, Longhi R, Gasparri A, Chen F, Pelagi M, Siccardi AG.

Eur J Biochem. 1996 Jan 15;235(1-2):275-80.


Production of mouse monoclonal antibodies directed against the oolemma of human and hamster oocytes by intra-splenic injection of oocytes.

Fusi FM, Gasparri AM, Pelagi M, De Santis CT, Grieco SE, Siccardi AG, Ferrari A.

Am J Reprod Immunol. 1995 Jan;33(1):122-30.


Immunodetection of secretogranin II in animal and human tissues by new monoclonal antibodies.

Pelagi M, Zanini A, Gasparri A, Ermellino L, Giudici AM, Ferrero S, Siccardi AG, Buffa R.

Regul Pept. 1992 Jun 11;39(2-3):201-14.


Supplemental Content

Loading ...
Support Center